Elevated triglycerides and low levels of high‐density lipoprotein as markers of disease activity in association with up‐regulation of the tumor necrosis factor α/tumor necrosis factor receptor system in systemic lupus erythematosus
Open Access
- 11 September 2003
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (9) , 2533-2540
Abstract
Objective: To investigate how blood lipid levels are related to disease activity, clinical characteristics, and serum levels of tumor necrosis factor α (TNFα) and its soluble type 1 and 2 receptors, sTNFR1 and sTNFR2, in systemic lupus erythematosus (SLE).Methods: Fasting blood samples were obtained from an unselected cohort of SLE patients at Karolinska Hospital (n = 208, mean ± SD age 45.7 ± 14.2 years). Disease activity was estimated using the SLE Disease Activity Measure (SLAM). Levels of circulating TNFα, sTNFR1, and sTNFR2 were determined by enzyme‐linked immunosorbent assay. Blood lipid levels obtained after overnight fasting were analyzed by routine chemistry.Results: Triglyceride (TG) levels were associated with the SLAM score (r = 0.48, P < 0.0001) and with the activities of TNFα (r = 0.29, P = 0.0001), sTNFR1 (r = 0.38, P < 0.0001), and sTNFR2 (r = 0.40, P < 0.0001). High‐density lipoprotein (HDL) levels were negatively associated with the SLAM score (r = −0.27, P = 0.0003) and with the activities of TNFα (r = −0.15, P = 0.04) and sTNFR2 (r = −0.19, P = 0.01). High levels of TGs, total cholesterol, TNFα, sTNFR1, and sTNFR2 all showed close correlations with the presence of nephritis and arterial disease (P < 0.05). In multiple logistic regression models, the TNFα activity and TG levels were independent determinants (P = 0.003 for both) of active disease (SLAM score ≥7).Conclusion: Dyslipoproteinemia with high TG/low HDL levels correlates with disease activity in SLE, and enhanced activity in the TNFα/sTNFR system seems to be an important underlying factor. Both dyslipoproteinemia and enhanced activity of the TNFα system are closely related to cardiovascular and renal manifestations in SLE, and thus both may serve as markers of more severe disease.Keywords
Funding Information
- King Gustaf V 80th Birthday Fund
- Swedish Society of Medicine
- Swedish Rheumatism Association
- Torsten and Ragnar Söderberg Foundation
- Swedish Heart-Lung Foundation
- Vårdal foundation
- Rheuma Research Foundation Margareta
- European Commission
- Swedish Science Fund
This publication has 43 references indexed in Scilit:
- Delayed Apoptotic Cell Clearance and Lupus-like Autoimmunity in Mice Lacking the c-mer Membrane Tyrosine KinaseJournal of Experimental Medicine, 2002
- Cytokines and systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2000
- Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropeniaAnnals of the Rheumatic Diseases, 1999
- Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α Levels and Disease Acitivity in Systemic Lupus ErythematosusClinical Rheumatology, 1999
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996
- High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion MoleculesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosusArthritis & Rheumatism, 1993
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993
- Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipidsAtherosclerosis, 1987
- The Hyperlipidemia of the Nephrotic SyndromeNew England Journal of Medicine, 1985